Page last updated: 2024-08-24

ziprasidone and Weight Gain

ziprasidone has been researched along with Weight Gain in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.33)	18.2507
2000's	31 (51.67)	29.6817
2010's	26 (43.33)	24.3611
2020's	1 (1.67)	2.80

Authors

Authors	Studies
Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S	1
Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C	1
Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT	1
Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J	1
Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K	1
Bellavia, A; Centorrino, F; Fitzmaurice, G; Jackson, JW; Valeri, L	1
Brixner, DI; Ghate, SR; Hashibe, M; Joy, E; Porucznik, CA; Said, Q	1
Calabrese, JR; Gao, K; Karayal, ON; Kolluri, S; Pappadopulos, E	1
Chen, AP; Juang, YY; Lee, CP	1
Hong, JP; Kim, MS; Park, S; Yi, KK	1
Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ	1
Dai, G; Zhang, Y	1
Beszlej, A; Bienkowski, P; Frydecka, D; Grzywacz, A; Mierzejewski, P; Samochowiec, A; Samochowiec, J; Trześniowska-Drukała, B; Tybura, P	1
Amado, JA; Ayesa-Arriola, R; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez García, O; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Tabares-Seisdedos, R	1
Brennan, MD; Ramsey, TL	1
Baer, L; Bobo, WV; Curren, L; Fava, M; Mischoulon, D; Papakostas, GI; Shelton, RC	1
Bai, YH; Cai, M; Chen, YC; Guo, L; McAlonan, GM; Tan, QR; Wang, HH; Wang, HN; Wang, Y; Wu, WJ; Zhang, RG; Zhang, YH; Zhang, ZJ	1
Chang, KD	1
Bogers, JP; Starrenburg, FC	1
Allison, DB; Giller, E; Loebel, A; Parsons, B; Romano, S; Siu, C; Williams, K	1
Lavedan, C; Thompson, A; Volpi, S	1
Baik, JH; Choi, SY; Noh, JS; Yoon, S	1
Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S	1
Harada, K; Irie, M; Kayama, Y; Kondo, Y; Matsuoka, N; Mihara, T; Ni, K; Shobo, M; Yamada, H	1
Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; von Wilmsdorff, M	1
Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL	1
Dadić-Hero, E; Grahovac, T; Knez, R; Kosec, T; Ružić, K; Sabljić, V	1
Dadić-Hero, E; Grahovac, T; Palijan, TZ; Petranović, D; Ružić, K; Sepić-Grahovac, D	1
Dadić-Hero, E; Grahovac, T; Ružić, K; Sabljić, V; Sepić-Grahovac, D	1
Andreotti, S; Gattaz, WF; Lima, FB; Passos-Bueno, MR; Sertié, AL; Sertié, RA; Suzuki, AM	1
Li, YM; Ou, JJ; Wu, RR; Zhao, JP	1
Cho, YM; Jeong, SW; Jung, H; Kim, JH; Kwak, SN; Kwon, OJ; Lee, KW; Oh, JE	1
Agid, O; Pappadopulos, E; Remington, G; Siu, CO; Vanderburg, D	1
Kaye, NS	1
Cohen, SA; Fitzgerald, BJ; Khan, A; Khan, SR	1
Arnold, G; Meisel, A; Winter, C; Zschenderlein, R	1
Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ	1
Bryois, Ch; Sahli, Ch	1
Citrome, L; Volavka, J	1
Bobes, J; Cañas, F; Mackell, J; Rejas, J	1
Murray, S; Pigott, T; Romano, SJ; Simpson, GM; Siu, CO; Weiden, P	1
Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS	1
Murray, S; Olié, JP; Spina, E; Yang, R	1
Kostulski, A; Rabe-Jabłońska, J; Wyszogrodzka-Kucharska, A	1
Jones, DN; Kalinichev, M; Rourke, C	1
Adams, DH; Ascher-Svanum, H; Edwards, SB; Kinon, BJ; Lipkovich, I; Siris, SG	1
de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D	1
Carpéné, C; Daviaud, D; de Beaurepaire, R; Even, PC; Minet-Ringuet, J; Prévot, D; Quignard-Boulange, A; Tomé, D; Valet, P; Visentin, V	1
Perlis, RH	1
Neill, JC; Reynolds, GP; Snigdha, S; Thumbi, C	1
Anjum, N; Fell, MJ; Marshall, KM; Neill, JC; Peltola, LM	1
Cater, JR; Delaney, MA; Hyman, SB; Malone, RP	1
Allison, DB; Cappelleri, JC; Chandler, LP; Cheskin, LJ; Fontaine, KR; Heo, M; Mentore, JL; Weiden, PJ	1
Allison, DB; Cappelleri, JC; Chandler, LP; Heo, M; Infante, MC; Mentore, JL; Weiden, PJ	1
McAskill, R; Taylor, DM	1
Casey, DE; Zorn, SH	1
Sussman, N	1
Goodnick, PJ	1
Caley, CF; Cooper, CK	1

Reviews

15 review(s) available for ziprasidone and Weight Gain

Article	Year
Atypical antipsychotics for disruptive behaviour disorders in children and youths. The Cochrane database of systematic reviews, 2017, 08-09, Volume: 8 Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Conduct Disorder; Depressive Disorder, Major; Dibenzothiazepines; Humans; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Weight Gain	2017
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:3 Topics: Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Stages; Thiazoles; Weight Gain	2013
The use of atypical antipsychotics in pediatric bipolar disorder. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Comorbidity; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Weight Gain	2008
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. European psychiatry : the journal of the Association of European Psychiatrists, 2009, Volume: 24, Issue:3 Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain	2009
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia research, 2010, Volume: 123, Issue:2-3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain	2010
[Psychotropics and weight gain]. Praxis, 2004, Aug-25, Volume: 93, Issue:35 Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain	2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgraduate medicine, 2004, Volume: 116, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain	2004
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities]. Przeglad lekarski, 2005, Volume: 62, Issue:9 Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles; Weight Gain	2005
Treatment of bipolar disorder: the evolving role of atypical antipsychotics. The American journal of managed care, 2007, Volume: 13, Issue:7 Suppl Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain	2007
Antipsychotic-induced weight gain: a comprehensive research synthesis. The American journal of psychiatry, 1999, Volume: 156, Issue:11 Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Confidence Intervals; Drug Administration Schedule; Humans; Molindone; Piperazines; Placebos; Psychotic Disorders; Research Design; Thiazoles; Treatment Outcome; Weight Gain	1999
Atypical antipsychotics and weight gain--a systematic review. Acta psychiatrica Scandinavica, 2000, Volume: 101, Issue:6 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Sulpiride; Thiazoles; Weight Gain	2000
The pharmacology of weight gain with antipsychotics. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 7 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Rats; Receptors, Neurotransmitter; Schizophrenia; Thiazoles; Weight Gain	2001
Review of atypical antipsychotics and weight gain. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 23 Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Hospitalization; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Research Design; Schizophrenia; Thiazoles; Weight Gain	2001
Ziprasidone: profile on safety. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:10 Topics: Antipsychotic Agents; Blood Glucose; Electrocardiography; Humans; Lipids; Piperazines; Prolactin; Psychotic Disorders; Thiazoles; Weight Gain	2001
Ziprasidone: the fifth atypical antipsychotic. The Annals of pharmacotherapy, 2002, Volume: 36, Issue:5 Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Headache; Humans; Injections, Intramuscular; Long QT Syndrome; Nausea; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain	2002

Trials

22 trial(s) available for ziprasidone and Weight Gain

Article	Year
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2020, Volume: 39 Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult	2020
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial. Schizophrenia research, 2019, Volume: 206 Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain	2019
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study. Behavioral and brain functions : BBF, 2013, Jul-19, Volume: 9 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Appetite; Benzodiazepines; Body Composition; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Energy Metabolism; Female; Humans; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Weight Gain; Young Adult	2013
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Human psychopharmacology, 2014, Volume: 29, Issue:1 Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss	2014
Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Human psychopharmacology, 2012, Volume: 27, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult	2012
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry research, 2014, Oct-30, Volume: 219, Issue:2 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Catechol O-Methyltransferase; Dopamine Plasma Membrane Transport Proteins; Female; Genotype; GluK3 Kainate Receptor; Humans; Male; Middle Aged; Monoamine Oxidase; Olanzapine; Overweight; Perazine; Piperazines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Kainic Acid; Schizophrenia, Paranoid; Serotonin Plasma Membrane Transport Proteins; Thiazoles; Weight Gain; Young Adult	2014
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophrenia research, 2014, Volume: 159, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sex Factors; Thiazoles; Weight Gain	2014
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. Schizophrenia research, 2014, Volume: 160, Issue:1-3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Female; Genotyping Techniques; Glucagon-Like Peptide-1 Receptor; Haplotypes; Humans; Male; Models, Genetic; Olanzapine; Perphenazine; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Receptors, Glucagon; Regression Analysis; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain; White People	2014
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. The Journal of clinical psychiatry, 2017, Volume: 78, Issue:4 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Selective Serotonin Reuptake Inhibitors; Thiazoles; Weight Gain; Young Adult	2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders. Journal of psychiatric research, 2017, Volume: 85 Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome; Weight Gain	2017
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry research, 2010, Feb-28, Volume: 175, Issue:3 Topics: Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Gene Frequency; Genotype; Humans; Isoxazoles; Male; Piperazines; Piperidines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2C; Schizophrenia; Thiazoles; Weight Gain	2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain	2010
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study. Pharmacopsychiatry, 2012, Volume: 45, Issue:5 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Dose-Response Relationship, Drug; Drug Monitoring; Episode of Care; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Weight Gain	2012
Early prediction of clinical and functional outcome in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:8 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Double-Blind Method; Drug Monitoring; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Models, Biological; Olanzapine; Patient Dropouts; Piperazines; Prognosis; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Weight Gain	2013
Ziprasidone augmentation of clozapine in 11 patients. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:2 Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain	2003
The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:1 Topics: Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Cholesterol; Female; Humans; Male; Middle Aged; Piperazines; Retrospective Studies; Thiazoles; Treatment Outcome; Weight Gain	2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. The American journal of psychiatry, 2004, Volume: 161, Issue:10 Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain	2004
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:8 Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Mental Disorders; Models, Econometric; Olanzapine; Outpatients; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Sensitivity and Specificity; Spain; Survival Analysis; Thiazoles; Treatment Outcome; Weight Gain	2004
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. The American journal of psychiatry, 2005, Volume: 162, Issue:8 Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Female; Humans; Lipids; Male; Olanzapine; Patient Compliance; Perphenazine; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain	2005
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International clinical psychopharmacology, 2006, Volume: 21, Issue:3 Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Hospitalization; Humans; Ketones; Male; Middle Aged; Movement Disorders; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome; Weight Gain; Weight Loss	2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:2 Topics: Antipsychotic Agents; Benzodiazepines; Depression; Glycated Hemoglobin; Humans; Olanzapine; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; United States; Weight Gain	2006

Other Studies

23 other study(ies) available for ziprasidone and Weight Gain

Article	Year
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:3 Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain	2003
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2007, Feb-27, Volume: 104, Issue:9 Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain	2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain	2007
Association between second-generation antipsychotics and changes in body mass index in adolescents. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2013, Volume: 52, Issue:3 Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Confidence Intervals; Dibenzothiazepines; Female; Humans; Male; Medical Audit; Olanzapine; Piperazines; Quetiapine Fumarate; Regression Analysis; Retrospective Studies; Risperidone; Thiazoles; United States; Weight Gain	2013
Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report. Clinical schizophrenia & related psychoses, 2015,Fall, Volume: 9, Issue:3 Topics: Adult; Antipsychotic Agents; Female; Humans; Metabolic Syndrome; Piperazines; Polypharmacy; Schizophrenia, Paranoid; Thiazoles; Weight Gain	2015
Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophrenia research, 2009, Volume: 110, Issue:1-3 Topics: Antipsychotic Agents; Databases, Bibliographic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors; Weight Gain	2009
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. Biochemical and biophysical research communications, 2010, Mar-05, Volume: 393, Issue:2 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Eating; Male; Mice; Mice, Knockout; Motor Activity; Olanzapine; Piperazines; Receptors, Dopamine D2; Risperidone; Thiazoles; Weight Gain	2010
Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behavioural brain research, 2011, Jan-20, Volume: 216, Issue:2 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Feeding Behavior; Hyperphagia; Male; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles; Weight Gain	2011
The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics (Sao Paulo, Brazil), 2010, Volume: 65, Issue:9 Topics: Animals; Antipsychotic Agents; Blotting, Western; Clozapine; Eating; Exploratory Behavior; Haloperidol; Hypothalamus; Leptin; Male; Motor Activity; Piperazines; Rats; Rats, Wistar; Receptors, Leptin; Thiazoles; Time Factors; Weight Gain	2010
Switching among antipsychotics--focus on side effects. Psychiatria Danubina, 2011, Volume: 23, Issue:1 Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Eruptions; Drug Substitution; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Pruritus; Sulpiride; Thiazoles; Weight Gain	2011
Antipsychotic treatment--side-effect and/or metabolic syndrome. Psychiatria Danubina, 2011, Volume: 23, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Drug Substitution; Female; Humans; Metabolic Syndrome; Olanzapine; Piperazines; Psychotherapy; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Weight Gain	2011
Weight gain--as possible predictor of metabolic syndrome. Psychiatria Danubina, 2011, Volume: 23, Issue:1 Topics: Adult; Antipsychotic Agents; Body Mass Index; Dibenzothiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Metabolic Syndrome; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Thiazoles; Weight Gain	2011
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Dec-01, Volume: 35, Issue:8 Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Olanzapine; Piperazines; Thiazoles; Weight Gain	2011
Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. Experimental & molecular medicine, 2012, Sep-30, Volume: 44, Issue:9 Topics: Adipocytes, Brown; Adipogenesis; Adipokines; Animals; Antipsychotic Agents; Cell Differentiation; Cell Line; Cell Survival; Clozapine; Dibenzothiazepines; Gene Expression Regulation; Humans; Mice; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles; Weight Gain	2012
Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:8 Topics: Adult; Antipsychotic Agents; Body Weight; Female; Humans; Obesity; Piperazines; Thiazoles; Tiapamil Hydrochloride; Tourette Syndrome; Weight Gain	2004
Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine. Behavioural pharmacology, 2006, Volume: 17, Issue:3 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Olanzapine; Piperazines; Prolactin; Rats; Rats, Sprague-Dawley; Thiazoles; Weight Gain	2006
A model for antipsychotic-induced obesity in the male rat. Psychopharmacology, 2006, Volume: 187, Issue:4 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Haloperidol; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Weight Gain	2006
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Molecular psychiatry, 2007, Volume: 12, Issue:6 Topics: Adipocytes; Animals; Antipsychotic Agents; Benzodiazepines; Cell Size; Drug Administration Schedule; Fatty Acid Synthases; Gene Expression Regulation; Glucose Transport Proteins, Facilitative; Haloperidol; Lipid Metabolism; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; RNA; Statistics, Nonparametric; Sterol Esterase; Thiazoles; Weight Gain	2007
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:5 Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Hyperphagia; Motor Activity; Olanzapine; Piperazines; Quinolones; Rats; Thiazoles; Weight Gain	2008
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:2 Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Dietary Fats; Drinking Behavior; Feeding Behavior; Female; Injections, Intraperitoneal; Olanzapine; Piperazines; Rats; Risperidone; Thiazoles; Weight Gain	2008
Ziprasidone in adolescents with autism: an open-label pilot study. Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:6 Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Cholesterol; Dose-Response Relationship, Drug; Dystonia; Electrocardiography; Female; Humans; Male; Pilot Projects; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychometrics; Thiazoles; Treatment Outcome; Weight Gain	2007
The distribution of body mass index among individuals with and without schizophrenia. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:4 Topics: Antipsychotic Agents; Body Mass Index; Clinical Trials as Topic; Comorbidity; Female; Health Surveys; Humans; Male; Obesity; Piperazines; Schizophrenia; Sex Factors; Thiazoles; United States; Weight Gain	1999
[Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain]. MMW Fortschritte der Medizin, 2002, May-06, Volume: Suppl 2 Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain	2002